We have established that in the Becker strain of pseudorabies virus (PRV), the glycoprotein glll gene is not essential for growth in cell culture. This was accomplished by construction and analysis of viral mutants containing two defined deletion mutations affecting the glll gene. These mutations were first constructed in vitro and introduced into Escherichia coli expression plasmids to verify structure and protein production. Each mutation was then crossed onto PRV by cotransfection of plasmid DNA and parental viral DNA by using glll-specific monoclonal antibodies as selective and screening reagents. One resultant virus strain, PRV-2, contained an in-frame deletion of a 402-base-pair (bp) Sacl fragment contained within the glll gene. Another virus strain, PRV-10, contained a deletion of a 1,480-bp XhoI fragment removing 230 bp of the upstream, putative transcriptional control sequences and 87% of the gIll coding sequence. The deletion mutants were compared with parental virus by analysis of virion DNA, glll specific RNA, and proteins reacting with glll specific antibodies. Upon infection of PK15 cells, the deletion mutants did not produce any proteins that reacted with two glll specific monoclonal antibodies. However, two species of truncated glycosylated proteins were observed in PRV-2 infected cells that reacted with antiserum raised against bacterially produced gIll protein.
Herpesviruses are large-enveloped-DNA viruses that infect a wide variety of organisms (28) . One general characteristic of the members of this diverse virus group is that they all encode a set of several distinct structural membrane glycoproteins localized both in the viral envelope and the membranes of infected cells (26, 28) . The function of the glycoproteins in the virus life cycle, the control of their synthesis, their transit through the protein localization machinery of the cell, and their pivotal role in host-virus interaction are active areas of research. One area of interest has been the comparison of glycoprotein genes and gene products from a variety of herpesviruses with the idea of finding shared units of structure and perhaps function. Even though considerable diversity exists among the herpesvirus glycoproteins in structure and function, some similarities in DNA and protein sequence have been identified (9, 21, 24, 28, 29, 31, 34) . In this report, we extend our analysis of a swine herpesvirus (pseudorabies virus [PRV] ) glycoprotein that shares significant homology to glycoprotein C of human herpes simplex virus type 1 (HSV-1) and that of HSV-2.
While considerable progress has been made in the identification and localization of glycoprotein genes for a variety of herpesviruses (3, 6, 9, 11, 13, 15, 17, 20, 22, 25, 31, 33, 35) , the functional and genetic analysis of glycoprotein gene expression has advanced more slowly. One reason is that until recently, few good selection or screening techniques existed for the direct analysis of glycoproteins. However, recombinant DNA technology and monoclonal antibodies have provided new tools for the analysis of the HSV glycoproteins (10, 14, 19, 20, 28) . An example of glycoprotein gene analysis with these new techniques is that done by Holland et al. (14) , using the glycoprotein C gene of HSV-1.
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These studies were successful because the HSV-1 gC gene is not essential for growth in tissue culture, and mutant isolation was relatively straightforward. As demonstrated by Holland et al., monoclonal antibodies proved to be useful for selecting infectious virus carrying a variety of mutations in the HSV-1 gC gene. As we will show in this report, a similar approach is possible in PRV with the glycoprotein glll gene. We are interested in bringing the combined tools of recombinant DNA technology and monoclonal antibodies to bear on a genetic analysis of herpesvirus glycoprotein structure and function. We have chosen to concentrate on the swine herpesvirus PRV. PRV encodes at least five distinct families of structural glycoproteins, as defined by studies with glycoprotein-specific monoclonal antibodies (13) . The gene for glycoprotein gI is located in the Us region and is apparently not essential for growth in tissue culture (2, 17, 18) . The glycoprotein gII gene shares significant homology to HSV glycoprotein gB and has been localized in the UL region at map position 0.1 (A. K. Robbins 142, 1985) . In addition to the envelope glycoproteins, an excreted glycoprotein called gX is encoded by a gene in the Us region (22) . We have identified a PRV glycoprotein gene at map position 0.4 and suggested that it encoded the gIII glycoprotein (24, 25) . The proof for this assertion is the subject of this report.
The function of PRV glycoprotein glll is not well understood; however, Hampl et al. (13) 
MATERIALS AND METHODS
Cell culture and viruses. Swine kidney cells (PK15) were grown in Dulbecco modified Eagle medium containing 10% heat-inactivated fetal bovine serum as described previously (25) .
The Becker strain of PRV has also been described previously (25) . PRV mutants derived from DNA transfection experiments were plaque purified two times before stocks were made for characterization. Virus stocks were prepared by infection of PK15 cells at a multiplicity of infection between 1 x 10-" and 5 x 10-5 PFU per cell.
Monoclonal antibodies and monospecific sera directed against PRV gIlI. The glll-specific monoclonal antibodies Ml and M16 were obtained from T. Ben-Porat and were made with the Ka strain of PRV (13) . These monoclonal antibodies showed essentially the same reactivity with the Becker strain of PRV (unpublished observations; this paper). One important feature of these monoclonal antibodies is that they reacted poorly with denatured gIll protein in Western blot analysis and not at all with glll fusion proteins produced in Escherichia coli (data not shown). They do neutralize PRV (Becker and Ka strains) in the presence or absence of complement and do immunoprecipitate glll proteins from infected cells (13; this paper). The gIl-specific monoclonal antibody M2 was also obtained from T. Ben Porat and was made with the Ka strain of PRV (13) . This monoclonal antibody reacts similarly with the three gll protein species (apparent molecular weights, 110,000, 68,000, and 55,000) of either the Becker or Ka strains of PRV, further establishing the close relationship of these two strains. 490 serum was raised in rabbits against denatured Cro-PRV glll protein produced in E. coli from expression plasmid pALM27 (previously designated p7/123AM [24] ). 490 serum reacts with both native and denatured PRV glll protein, as determined by direct staining of plaques (black plaque assay [15, 27] (12) . After a 4-h incubation at 37°C, the transfected cells were washed with growth medium, subjected to a 3-min shock with 15% glycerol, and washed twice, and then fresh growth medium was added. After a subsequent 12-h incubation, guinea pig complement (5%) and the glll-specific monoclonal antibodies Ml and M16 (final concentration of each antibody, 0.6 ,ug/ml) were added.
In the presence of complement, these monoclonal antibodies neutralized the infectivity of parental PRV (15, 27) . Plaques that did not react with glll-specific antibody were picked and purified twice before analysis.
Mutant virus was named by the number of the pALM plasmid that was used to make it; i.e., PRV-2 contains the deletion carried by pALM2 and PRV-10 carries the deletion specified by pALM10.
Preparation of virions and cell extracts for immunoprecipitations. The procedure used for virion purification was as described by Ben-Porat et al. (1) (Fig. 1 ). Deletions affecting glll were first constructed in the E. coli expression plasmid pALM3 ( Fig. 2A) . In this plasmid, transcription of the Cro-PRV glll hybrid gene was directed from the tac promoter under control of the Lac repressor. pALM3 produced significant quantities of a Cro-PRV glll fusion protein that accumulated to approximately 3 to 5% of the total cell protein (Fig. 3) . As determined by DNA sequence analysis (data not shown), the amino-terminal 23 amino acids derived from the bacteriophage lambda Cro protein were fused to the first amino acid (Met) of glll. In pALM3, the coding sequence terminated at the natural translation stop signal (TGA) after amino acid 479, followed by approximately 1 3 . Induction of Cro-PRVgIII fusion proteins from expression plasmids. E. coli NF1829, containing either pALM2, pALM3, or pALM10, was grown in L-broth containing 100 pug of ampicillin per ml. Fusion proteins were induced by addition of isopropyl-P-Dthiogalactopyranoside (final concentration, of 1 mM). A 3-ml sample from each induced culture was harvested at 4 h postinduction. The Cro-PRVgIII fusion proteins were found primarily in insoluble aggregates and were prepared as described previously (36) . The aggregated proteins were fractionated by electrophoresis on a 10% SDS-polyacrylamide gel and then stained with Coomassie blue. system, we were able not only to verify the structure and translation products of the mutants before crossing them onto PRV, but also to produce the unglycosylated and unprocessed forms of mutant gIII fusion proteins in reasonable quantities for use as reagents, e.g., for raising monospecific, polyvalent antisera.
All plasmids were constructed by standard recombinant DNA techniques (8, 16) . The starting plasmid pALM3, described above, was a recombinant of pALM13 and pALM18, both of which were described previously as ptacNB and pK64, respectively (24) . pALM2 ( Fig. 2A) contained an in-frame deletion within the gIll gene and produces a truncated fusion protein (Fig.  3) . It was constructed by digesting pALM3 with Sacl, religating, and selecting a plasmid that had lost the 402-bp internal Sacl fragment. pALM2 contained a unique SacI site defining the 402-bp deletion.
pALM11 was needed as an intermediate in the construction of pALM10 and pALM15 (Fig. 2B) . It was constructed as follows: pALM12 (formerly p7/123 [24] ) was digested with SphI, and the resulting single-stranded ends were removed by using the 3'-5' exonuclease activity of the Klenow fragment of DNA polymerase I. The DNA was then digested with BamHI, and the 2,500-bp fragment was ligated into the SmaI-BamHI sites of pHK412 (25) . pALM10 was constructed to contain an XhoI deletion removing most of the gIII gene including 230 bp of upstream DNA (Fig. 2B) . pALM10 was derived from pALM3 and pALM11 as follows. DNA from both plasmids was digested with PstI and XhoI. The 1,840-bp fragment of pALM11 and the 3,670-bp fragment of pALM3 were purified and ligated with T4 DNA ligase. The resulting plasmid, pALM10, lacked all of the gIll gene except for 186 bp encoding the carboxy terminus. It also retained the tac promoter-operator and translation elements of the pALM3 expression vector.
pALM15 contained 3,600 bp of PRV DNA, including the entire 1,437-bp gIII coding sequence (Fig. 2C ). pALM15 is a derivative of pALM3 and pALM11 constructed as follows. DNA from both plasmids was digested with PstI and BamHI. The 3,100-bp fragment of pALM3 and a 3,400-bp fragment from pALM11 were purified and ligated by using T4 DNA ligase. pALM15 also retained the tac promoteroperator and translation elements of the pALM3 expression vector.
Preparation of Cro-PRV fusion proteins expressed in E.
coli. The techniques used for producing and purifying Cro-PRV fusion proteins expressed in E. coli have been described previously (24, 36) .
RESULTS
Analysis of mutant gIll expression plasmids. Two gIll deletion mutations were constructed in bacterial expression plasmids for ultimate insertion into the PRV genome. These mutations included (i) an in-frame deletion of a 402-bp SacI fragment in the glll coding sequence, predicted to result in production of a truncated glll protein, and (ii) a deletion of a 1.48-kilobase (kb) XhoI fragment, removing 87% of the glll gene, including the amino terminus and 230 bp of upstream DNA. This deletion left behind the extreme 186 bp encoding the carboxy terminus of the glll gene. The plasmids with these deletions were pALM2 and pALM10, respectively (Fig. 2) . A Coomassie-stained SDS-polyacrylamide gel was made of the insoluble aggregated proteins produced by isopropyl-,-D-thiogalactopyranoside induction of cells harboring pALM3 (Fig. 3, lane 2) , pALM2 (lane 3), and pALM10 (lane 4). pALM3 produced a 64-kilodalton (kDa) Cro-PRVgIII fusion protein, pALM2 produced a smaller fusion protein (43 kDa), and pALM10 produced no apparent fusion protein upon induction. As has been observed previously, there was a discrepancy between the predicted molecular mass of the fusion protein as deduced from the DNA sequence and the observed molecular mass calculated from migration in SDSpolyacrylamide gel electrophoresis in that the apparent molecular mass greater than the predicted mass (24) . This gel artifact was also apparent for proteins extracted from virus- A white plaque was isolated and purified from the pALM2 transfection, and one was likewise obtained from the pALM10 transfection. These mutant viruses were designated PRV-2 and PRV-10, respectively.
By analyzing the viral DNA, we determined that the deletion constructed in each plasmid had indeed been crossed onto the virus (Fig. 4) . For these experiments, viral DNA was isolated from nucleocapsids of parental PRV and the gIll-defective mutants PRV-2 and PRV-10. The DNA was digested with PstI and XhoI, fractionated on an agarose gel, transferred to nitrocellulose, and hybridized with a 32P-labeled pALM15 probe. The gIII gene was located approximately in the center of a 4.3-kb PstI fragment ( Fig. 1  and 4 ). There were three XhoI sites in this PstI fragment, two upstream of the gene and one within the gIll coding sequence near the carboxy terminus. The 1.48-kb XhoI fragment defined by the site 230 bp upstream of the gIll gene and the site within the gIll gene was the critical fragment for this analysis. All DNA samples were digested with PstI and XhoI. When pALM15 was used as a probe, the patterns shown in Fig. 4 were observed. The parental pattern is shown in lane 1. Note the two fragments of 1.3 and 0.95 kb and the 1.48-kb internal XhoI fragment. In PRV-2, which should contain a 402-bp deletion within the glIl gene, the 1.3-and 0.95-kb fragments were unchanged, but the 1.48-kb internal XhoI fragment now migrated as a 1.1-kb fragment (Fig. 4, lane 2) . Similarly, in PRV-10, which should contain a precise deletion of the 1.48-kb internal XhoI fragment, only the 1.3-and 0.95-kb fragments were seen (lane 3) . In other analyses with Sacl, we found that PRV-2 contained a precise deletion of the 402-bp internal gIII Sacl fragment, leaving a single SacI site in the truncated gIII gene (data not shown). Thus, the two site specific deletions constructed in vitro were transferred precisely by recombination to PRV.
gIII-specific RNA in cells infected with PRV gIIl deletion mutants. Cytoplasmic RNA transcribed from the gIll gene was analyzed by using the Northern blot technique as described in Materials and Methods. The probe was nicktranslated pALM15, which contained the entire gIll gene as well as 1.2 kb of upstream and 1.0 kb of downstream PRV DNA (Fig. 5) . Cytoplasmic RNA was extracted from PK15 cells infected with parental PRV, PRV-2, and PRV-10 and also from uninfected PK15 cells as a control. No hybridization was observed with control RNA from uninfected cells (Fig. 5, lane 1) . As reported by Robbins et al. (24), a 1.55-kb gIll specific mRNA was observed from parental PRV infection (Fig. 5, lane 2) . The other minor bands corresponded to PRV-specific RNAs outside the gIll gene and served as internal controls. The proof that the 1.55-kb RNA was indeed gIll specific and that the minor RNAs were not was established by the RNA produced by the gIll deletions PRV-2 and PRV-10, which hybridized to the probe (Fig. 5,  lanes 3 and 4) . PRV-2 carried a 402-bp deletion within the gIII gene, and, as predicted, the 1.55-kb message was absent and replaced by a 1.15-kb transcript (Fig. 5, lane 4) . The minor RNA species were unchanged. Similarly, produced no 1.55-kb transcript, as predicted, since the 1.48-kb Xhol deletion removed 87% of the gIll coding sequence as well as 230 bp upstream, presumably encoding at least the gIll promoter (Fig. 5) . In this case, the minor A 0 J. VIROL. RNA species (1.75 and 1 kb) remained constant in quantity and size, but two new species of 2.3 and 1.3 kb were observed that must have resulted from the XhoI deletion. It is likely that these minor species originated from sequences upstream of the gIII gene. The two remaining minor species that were unaltered must have been encoded by sequences outside the XhoI deletion and downstream of the glll gene.
4-10's IVC
In vitro translation of late RNA isolated from cells infected with PRV deletion mutants. PRV gIll-specific primary translation products were identified by immunoprecipitation of proteins made by in vitro translation of total cytoplasmic RNA as described in Materials and Methods. The RNA was isolated from cells 16 h after infection with either parental PRV or PRV-2 carrying the Sacl glll deletion (see Materials and Methods). The translation products were immunoprecipitated with 490 serum and analyzed on a 10% SDS-polyacrylamide gel (Fig. 6) . Although the predicted molecular mass of the PRV glll primary translation product is approximately 51 kDa (24), the apparent molecular mass of the in vitro translation product was 57 kDa (Fig. 6, lane 2) . PRV-2 carried the 402-bp Sacl deletion which is predicted to result in a deletion of 134 amino acids that should yield a truncated protein of 37 kDa. The apparent molecular mass was 44 kDa (Fig. 6, lane 3) . These experiments corroborate the data shown in Fig. 3 with bacterially produced Cro-glIl fusion proteins, in which the apparent molecular mass was greater than predicted. We conclude that the altered mobility of gIll peptides in SDS-polyacrylamide gels was due to structural features imposed by the primary protein sequence.
Immunoprecipitation of proteins produced by glll deletion mutants. We analyzed the gIll-specific proteins produced by parental PRV and the two PRV gIll deletion mutants by immunoprecipitation. Two reagents were critical for this analysis. One was the monospecific, polyclonal 490 serum made against bacterially produced Cro-PRV gIII fusion protein (see Materials and Methods and reference 24). The other was the PRV gIll-specific monoclonal antibody Ml (13). Since deletions PRV-2 and PRV-10 were both selected by their inability to react with the Ml and M16 monoclonal antibodies, we did not expect them to immunoprecipitate the mutant gIll proteins from infected cells. On the other hand, since the polyvalent 490 serum reacts with denatured and native gIll protein (24), we expected it to react with altered variants of gIll that did not react with Ml and M16. The data shown below substantiate this expectation.
PK15 cells were infected with parental PRV or with deletion mutant PRV-2 or PRV-10, labeled with [3H]glucosamine for 16 h, and immunoprecipitated as described previously (24, 25) . The gIl-specific monoclonal antibody M2 was included as a control. Ml monoclonal antibody specifically immunoprecipitated a characteristic diffuse band of glycosylated gIll protein at an apparent molecular mass of about 92 kDa (Fig. 7, lane 1) . The 490 serum immunoprecipitated the same material plus a sharper band at an apparent molecular mass of 74 kDa (Fig. 7, lane 2 ) that presumably represented a gIll protein of a different glycosylation state (perhaps a precursor form). A similar observation was reported for HSV-1 gC (7). Alternatively, the 74-kDa protein may represent a major and specific degradation product of the 92-kDa protein produced during preparation of the cell extracts. Some support for the former hypothesis was obtained from a similar analysis of PRV-2 infected cells (Fig. 7, lanes 4, 5, and 6 ). PRV-2 is predicted to produce a truncated gIll protein due to the 420-bp internal deletion. The Ml monoclonal antibody used in selection showed no specific reaction (Fig. 7, lane 4) , but the 490 serum immunoprecipitated two truncated forms of gIll at apparent molecular masses of about 68 (diffuse) and 43 (sharp) kDa (lane 5) . The relationship of the two truncated species of gIll produced by PRV-2 corresponded well to that of the 92-and 74-kDa forms seen for authentic gIll produced after infection with parental PRV. These results were more consistent with a precursor-product relationship than with degradation.
Extracts made from PRV-10-infected cells showed no evidence of immunoreactivity with either Ml or 490 antisera (Fig. 7, lanes 7 and 8) . Similar results were obtained by using the M16 monoclonal antibody (data not shown). The M2 monoclonal antibody control indicated that the gIl glycoprotein family was unchanged in either deletion mutant (Fig. 7,  lanes 3, 6, and 9 Growth of PRV gIll mutants. The lack of the gIll gene in PRV-10 was not entirely without effect since we routinely observed that titers of mutant stocks prepared by lowmultiplicity infection were variable and could be 10-to 20-fold lower than comparably prepared parental virus stocks. This result was unexpected since measurements of mRNA (Fig. 5 ) and the gIl glycoprotein family (Fig. 7) showed essentially no differences, other than those expected for the gIll gene, when compared with those of parental PRV. Moreover, in DNA transfection experiments, parental PRV, PRV-2, and PRV-10 were indistinguishable, giving about 3,000 plaques per pLg of input viral DNA. Finally, in high-multiplicity infections (10 PFU per cell), cytopathic effect was seen at approximately the same time and to the same extent for gIll-defective mutants and parental virus.
Virus particles in cells infected with either parental PRV or PRV-10 were visualized in an electron microscope (Fig.  8) . At (24, 25) was indeed the PRV gIll gene, and (ii) like its related homolog, glycoprotein C of HSV-1 and HSV-2, the PRV gIII gene was not absolutely essential for growth in vitro.
The identification of the glycoprotein gene at map position 0.4 as gIII (Fig. 1 ) depended on two specific reagents: (i) the monoclonal antibodies MI and M16, characterized by Hampl et al. (13) , which defined the gIII family of glycoproteins, and (ii) the monospecific, polyvalent 490 serum made against the putative Cro-glll fusion protein expressed in E. coli. Since the glll-specific monoclonal antibodies reacted poorly with denatured authentic glll, proteins made by in vitro translation, and bacterially produced proteins thought to be gIII, the direct identification of the glll gene was not straightforward. However, in this report we confirmed its identity by constructing specific deletions that predictably altered the putative gIll gene and gene product and then demonstrating that we could cross these mutations onto PRV by selecting and screening for recombinants resistant to gIII-specific monoclonal antibodies. With these defined deletion mutants, it was possible to compare gIII specific gene products in parental and mutant virus infections as well as to determine the behavior of the primary translation products by using in vitro translation.
Although the predicted amino acid sequence of glll suggested about 20% homology to the nonessential HSV-1 and HSV-2 gC glycoprotein (24), we had no other reason to believe that glll would be similarily expendable for PRV. Therefore, our initial concern was that these deletions could be lethal when recombined back onto PRV. For that reason, defined, easily verifiable deletions were absolutely essential, because in using the gIII-specific monoclonal antibodies in the selection and screening, we had to avoid simply selecting spontaneous gIll mutations that did not react with the monoclonal antibodies. It would be highly unlikely that either the specific Sacl or XhoI deletion would arise by a spontaneous event.
The results were clear. Both deletions were crossed easily onto PRV, and, indeed, the resulting viral mutants were nonreactive with glll-specific monoclonal antibodies. Moreover, the deletions permitted unambiguous assignment of the 92-and 74-kDa family of glycosylated proteins as products of the same gene because both were altered accordingly to 68 and 43 kDa by the internal glll deletion carried by PRV-2.
This entire group of proteins was not made by the essentially complete gIII deletion carried by PRV-10.
Previously, glll was reported as a virion envelope protein of 98 kDa (13) ; however, by using our gel system and standards, we calculated the apparent molecular mass to be 92 kDa. As did Hampl et al. (13) on July 8, 2017 by guest http://jvi.asm.org/ Downloaded from either a precursor form of the 92-kDa protein or a form of gIll destined for a cellular location other than the virus envelope. A similar situation of two distinct glycosylated proteins is seen for the related gC protein of HSV-1 (7) .
It is interesting that the internal Sacl deletion carried by PRV-2 removed five of the eight potential N-linked glycosylation sites predicted from the DNA sequence (24) . However, it appears that both the 68-and 43-kDa forms were labeled with glucosamine to approximately the same extent as were the 92-and 74-kDa forms of glll in a parental infection (Fig. 7) . The extent and function of N-linked and 0-linked glycosylation are currently under investigation.
Little is known concerning the role of glll in the infectious cycle of PRV. Hampl et al. (13) have demonstrated that, of the monoclonal antibodies to PRV glycoproteins tested, only those directed against glll prevent infectivity; antibodies against the other glycoproteins are ineffective. Since we were able to delete the gIII gene and transfer this deletion to infectious virus, it is unlikely that the gIII gene is primarily responsible for adsorption and infection of cells in tissue culture. However, it should be noted that the absence of glll was not without effect. PRV-10 stocks were variable in titer and often 10-to 20-fold lower than parental virus stocks. At this time it is not clear whether this result is due to the absence of glll protein or to effects of the deletion in PRV-10 on upstream PRV DNA. Complementation experiments must be done to determine whether this effect can be compensated by supplying a good glll gene.
We have observed that the truncated gIII protein expressed by PRV-2 is efficiently inserted into the virus envelope (M. E. Whealy, A. K. Robbins, and L. W. Enquist, manuscript in preparation). Therefore, it is apparent that PRV can exist as a nominally normal infectious virus in cell culture with no gIII (PRV-10) or with a truncated form of glll in the virus envelope (PRV-2).
Ben-Porat et al. (2) have shown that the Bartha and Norden vaccine strains of PRV have deletions in the Us region, removing the coding sequences for glycoprotein gI. These gI-defective viruses grew well in culture but were defective in the release of virions from certain cell types. We have not been exhaustive in our search for defects in the glll deletion mutants. Further studies are in progress to test these viral mutants for virus release and host range in cell culture as well as pathogenicity in animals.
As a final point, we have used E. coli plasmid expression vectors as intermediates in the construction of viral mutants to prepare in quantity the mutant protein of interest devoid of eucaryotic posttranscriptional modifications. The 490 serum used in this paper is an example of such a reagent. We have found that such proteins are good immunogens for the preparation of monospecific, polyvalent sera (24, 25, 36 ; this report). Since these bacterially produced fusion proteins are generally denatured when injected into animals, the antibodies produced often react with not only authentic native viral proteins, but also with denatured viral protein precursors and products in Western blot analyses (25, 36) .
